Grants for Small businesses - Federal

This funding opportunity provides financial support to research institutions for developing and conducting multi-institutional clinical trials focused on cancer control, prevention, and care delivery in community settings.

USAID/Senegals Sahel Regional Office (USAID/Senegal/SRO) ADDENDUM #1 - CALL FOR CONCEPT PAPERS USAID Strengthening Information Integrity and Resilience (IIR) in the Sahel USAID Sahel Information Integrity Annual Program Statement No. 72068524APS00003 Issuance Date: June 28, 2024 Closing Date: July 30, 2024 Questions Due Date for this APS Addendum: July 9, 2025 Dear Prospective Applicants: This is an Addendum to the USAID Sahel Information Integrity Annual Program Statement (APS) (No.72068524APS00003). All interested organizations should carefully review both this Addendum AND the full APS, which can be found here in grants.gov . Important information contained in the APS announcement is not necessarily repeated in this specific Addendum. This activity is authorized under the Foreign Assistance Act of 1961, as amended. Through this Addendum #1 to APS No. 72068524APS00003, USAID/Senegal/SRO is requesting the submission of concept papers focused on Strengthening Information Integrity and Resilience (IIR) in the Sahel. Concept papers should describe a nimble and adaptive approach for supporting key actors in local and regional information ecosystems to be more effective in advancing information integrity and resilience in their local and regional systems. TARGET COUNTRIES: All three objectives of this activity (as outlined under technical focus below) must be addressed in all of the following countries, which fall under the management authority of USAID/Senegal/SRO: Burkina Faso Chad Mauritania Objective 2 under this APS (which relates to strengthening regional networks) may also create opportunities for partner organizations in Cabo Verde, The Gambia, Guinea-Bissau, Mali, Niger, and Senegal based on prior approval from USAID. Under this Addendum, subject to the availability of funds, USAID anticipates making one award. USAID also reserves the right to make no awards. The total USAID funds anticipated is $15,000,000. USAID contemplates a start date for the award beginning on or about December 1, 2024, with a period of performance of up to five years. Applicants should send general questions about the below information by email to USAID primary and secondary points of contact, Ms. Aminata Diallo, at amdiallo@usaid.gov and Robert Almosd at ralmosd@usaid.gov, respectively. See " related Documents" Tab for the full Addendum Thank you for your interest in USAID Programs. Sincerely,

This funding opportunity provides financial support to shipyards and training organizations to improve the repair capabilities and workforce skills for non-nuclear U.S. Navy vessels.

This grant provides funding to support promising postdoctoral researchers in neuroscience, enabling them to receive advanced training and mentorship in a focused research environment.

This funding opportunity provides financial support to early-career researchers currently holding specific NIAMS career development awards, helping them advance their research projects and transition to independent research careers in arthritis, musculoskeletal, and skin diseases.

Grant Title: Centers on the Demography and Economics of Aging, Including Alzheimer's Disease and Alzheimer's Disease-Related Dementias (AD/ADRD) (D and E Centers) (P30 Clinical Trial Optional) aims to support interdisciplinary research centers that focus on the social science aspects of aging, particularly related to health disparities, economic impacts, and caregiving for dementia, while fostering collaboration among diverse scholars and institutions.

This funding opportunity provides financial support to small businesses that previously received Phase I SBIR grants from NIST, enabling them to further develop their innovative projects into commercially viable products or services.

This funding opportunity supports innovative projects that develop advanced high-voltage direct current technologies to enhance the resilience and sustainability of the U.S. energy grid, targeting domestic entities and collaborations focused on improving power transmission systems.

The National Cancer Institute (NCI) intends to issue the U54 Specialized Programs of Research Excellence in Cancer Health Disparities and Minority Health (CHD-MH SPORE) notice of funding opportunity (NOFO). The program will support a network of multidisciplinary, multi-institutional U54 CHD-MH SPOREs, which are multi-project awards uniquely focused on health disparities and/or minority health translational research for improved prevention, early detection, diagnosis, and treatment of cancer in populations who are underserved. U54 CHD-MH SPOREs can investigate more than one cancer type in underserved populations, including groups of highly related cancers (e.g., gastrointestinal or head and neck). The research supported through this program must be translational and must stem from research on human biology, addressing the interplay of various determinants of health with the biology of the disease. U54 CHD-MH SPORE projects must have the goal of reaching a translational human endpoint within the project period of the grant, which may include a clinical trial. This Notice of Intent to Publish is being provided to allow sufficient time for applicants to develop strong applications. The NOFO is expected to be published in late winter 2024 with only one expected application due date in late September 2024.

This grant provides funding for research projects that explore the complex processes of cancer metastasis, encouraging collaboration among institutions to improve understanding and treatment of metastatic diseases.

This funding opportunity supports research on policies affecting tobacco, alcohol, and cannabis use in underserved communities, aiming to promote health equity and reduce disparities in substance exposure and use.

This funding opportunity provides financial support for research aimed at improving the spread and implementation of effective health interventions, particularly in underserved communities, with a focus on promoting health equity and addressing health disparities.

This funding opportunity supports small businesses in developing innovative, non-addictive therapies and technologies for effective pain management, addressing the urgent need for alternatives to opioid treatments.

This funding opportunity provides financial support for organizations to host conferences and workshops that promote research integrity and ethical practices in research across various disciplines.

This funding opportunity provides financial support to local organizations in Zimbabwe to implement comprehensive HIV prevention and treatment programs, focusing on key populations and improving health services to achieve and maintain epidemic control.

This funding opportunity supports the establishment of research centers that create advanced animal models for studying diseases, enabling better translation of genetic research into human health applications, and is open to a variety of eligible institutions and organizations.

This funding opportunity provides resources to research centers focused on skin diseases, encouraging collaboration and innovation among a diverse range of institutions and organizations.

This funding opportunity supports innovative research projects focused on developing and testing radionuclide-based cancer therapies, particularly in preclinical settings, to improve treatment outcomes and understanding of their effects on tumors and normal tissues.

This funding opportunity seeks innovative research proposals from various entities, including businesses and universities, to develop groundbreaking technologies for national security, focusing on areas like novel materials, quantum computing, and artificial intelligence.

Key aspects of the TSA: Multidisciplinary Collaboration: The success of the project should depend on the unique skills and perspectives of each partner. The application must clearly define the synergistic components that will facilitate and accelerate progress in melanoma in a way that could not be accomplished through independent efforts. The plans for interactions among all PIs and institutions involved must be clearly articulated. Collectively, the members of the research team should represent the appropriate diversity of expertise necessary for addressing the proposed research question. Participating institutions must be willing to resolve potential intellectual and material property issues and remove institutional barriers to achieving high levels of cooperation. The following components of the proposed multidisciplinary collaboration are encouraged but not required: It is strongly encouraged that the research team has a least one investigator, key personnel, or consultant who can provide input on the ultimate utility/applicability (short- or long-term) of the anticipated outcome(s) to the melanoma field and/or patient care. The inclusion of an early-career investigator is encouraged. An early-career investigator is defined as an independent, early-career researcher or physician-scientist within 7 years of receiving their first faculty appointment by the time of the full application deadline. Investigators in mentored positions, (e.g., postdoctoral fellows) are not eligible to be named as a PI on a TSA application. The inclusion of a military and/or U.S. Department of Veterans Affairs (VA) investigator is encouraged. A military or VA investigator is defined as an investigator who is active-duty, active reserve, active duty detailed to agencies outside of the Department of Defense (DOD), civilian DOD investigators, or an investigator at a VA research facility. If included as PI on the research team, the military/VA investigator should have a substantial role in the research and should not be included only for access to active-duty military and/or VA populations. Impact: The application must articulate the impact the proposed work, including basic research, will have on melanoma research and/or patient care. Outcomes from this award are expected to expedite the advancement of promising ideas toward clinical applications and/or improve the current state of the science/technology in the melanoma field. The proposed research must relate to at least one of the FY24 MRP Focus Areas in Section II.A.1. Preliminary Data Required: Applications must include preliminary data to support feasibility of the study. However, these data do not necessarily need to be derived from melanoma studies. Any unpublished, preliminary data presented should originate from the laboratory of at least one of the PIs or other member(s) of the research team.